Enhanced expression of the c-myc protooncogene in high-grade human prostate cancers.
about
Skp2: a novel potential therapeutic target for prostate cancerMolecular pathology of prostate cancerU94 alters FN1 and ANGPTL4 gene expression and inhibits tumorigenesis of prostate cancer cell line PC3.SIRT3 inhibits prostate cancer by destabilizing oncoprotein c-MYC through regulation of the PI3K/Akt pathway.Mxi1, a Myc antagonist, suppresses proliferation of DU145 human prostate cellsEvaluation of the 8q24 prostate cancer risk locus and MYC expression.Identification of differentially expressed genes associated with androgen-independent growth of prostate cancer.Genetic and genomic analysis modeling of germline c-MYC overexpression and cancer susceptibilityNeuroendocrine differentiation in prostatic carcinoma.A method for detecting long non-coding RNAs with tiled RNA expression microarrays.Differential expression of the ccn3 (nov) proto-oncogene in human prostate cell lines and tissues.Multiple loci with different cancer specificities within the 8q24 gene desert.mCOPA: analysis of heterogeneous features in cancer expression data.Alterations in nucleolar structure and gene expression programs in prostatic neoplasia are driven by the MYC oncogene.Cytogenetics and molecular genetics of cancer of the prostate.Nuclear MYC protein overexpression is an early alteration in human prostate carcinogenesis.Genetic alterations in hormone-refractory recurrent prostate carcinomasDetection of the apoptosis-suppressing oncoprotein bc1-2 in hormone-refractory human prostate cancers.Differentially Expressed Genes and Signature Pathways of Human Prostate Cancer.The role of prevalence in the diagnosis of prostate cancer.Screening key microRNAs for castration-resistant prostate cancer based on miRNA/mRNA functional synergistic network.Polygenic susceptibility to breast cancer: current state-of-the-art.Therapeutic Approaches Targeting MYC-Driven Prostate CancerAdaptation and clonal selection models of castration-resistant prostate cancer: current perspective.Disruption of prostate epithelial differentiation pathways and prostate cancer development.Prostatic adenocarcinoma. Carcinogenesis and growth.Assessment of the biologic markers p53, Ki-67, and apoptotic index as predictive indicators of prostate carcinoma recurrence after surgery.Coamplification of prostate stem cell antigen (PSCA) and MYC in locally advanced prostate cancer.Role of miRNA let-7 and its major targets in prostate cancer.No germline mutations in the dimerization domain of MXI1 in prostate cancer clusters. The CRC/BPG UK Familial Prostate Cancer Study Collaborators. Cancer Research Campaign/British Prostate Group.MYC and Prostate CancerCastration therapy rapidly induces apoptosis in a minority and decreases cell proliferation in a majority of human prostatic tumorsLoss of heterozygosity (LOH), malignancy grade and clonality in microdissected prostate cancer.Genetic alterations in benign prostatic hyperplasia patients.A dock derived compound against laminin receptor (37 LR) exhibits anti-cancer properties in a prostate cancer cell line model.Novel anti-androgen receptor signaling agents: Understanding the mechanisms of resistance.
P2860
Q24625558-C1EAD0BA-A03B-472A-B662-A2CC43A72BF5Q24672410-941B8AE6-C767-47BA-898C-A269072A5FCEQ24811943-3D2F3550-C7AD-485E-B856-7F8F1C7AB4A6Q27341759-225B4CC6-4332-4443-A74E-C127EEE44BF2Q28188728-695DC4A9-F287-4EE4-8EA5-33E7E1434FBEQ30494853-E15CDEF7-5B42-4C27-825E-96C6708DE931Q30835299-47288444-0747-45BF-BAFE-B96371A32378Q33314433-128A5833-DEAE-4278-B978-A24A2F3BC558Q33604393-BB5755BB-2A2C-4E74-969A-BC1CECC65B11Q33768979-BF6F156C-701C-4F39-B9E1-B05C272D0C0CQ33918779-BC59DE2D-EAA7-496D-901D-67A66E1F49B6Q33988405-1A5B0B0E-2111-46B4-AE74-1A7A37E30455Q34502379-9AF93ACB-2914-4FB3-869E-EDB99EECC864Q34805348-B4338FCE-DEFD-4281-9E8F-B5D729765D21Q34984193-2F1B09F2-76F1-4694-B177-D8C53CB3E92FQ35207795-67908609-0B1D-47FB-A7E7-E1A3BEAB0D65Q35753171-2E354711-46B6-4B4F-97D8-BE2749533C2EQ35833088-B0267F7A-9185-43DB-9A06-F18E0B94A5E4Q35873154-AFE2F4E5-645A-455D-BF89-52728FE22A55Q36555644-8406A24F-ECB3-432C-9838-53BF8D91E1EEQ36685517-25B55836-CFE3-42AC-B16E-FC15785C1F82Q37062641-415D02A2-9FC4-4601-B2D4-8423BFB47EFDQ37676253-25DF9E4C-5681-4693-8572-2E5E91422D04Q38060845-C2811EF7-D4D6-498C-A7AC-8C85893038BBQ38160495-C02F7D6A-D946-498E-82F3-339048734015Q38535009-5729E182-F13C-4E9D-9BA3-3F77619BBBF5Q40872928-03388B1D-AB1A-4F44-B776-27CA9D5BF2C8Q41702856-21CCC342-BF70-44EF-BC20-1EC1BB76343AQ41890041-D2B55FE0-0201-45B0-B752-37A5497B64DCQ41931445-DF4BA6C7-E663-467E-BC78-EE524F765796Q42731671-5C1290CA-5295-49BE-A7E6-F121FBFD7E26Q42787650-EB771328-16E6-435B-BEF8-09B511CB46EDQ43201521-6C14AD8A-01EA-4FE6-BE67-B25EA8D32415Q47095728-861B8CFC-6035-4F1C-80F5-16D616CCFCB4Q49787711-664BA977-31A9-425D-ADF9-A7B07502C65FQ54949068-F0C80BE2-F3F9-4EE3-BBFE-C07AF1064C35
P2860
Enhanced expression of the c-myc protooncogene in high-grade human prostate cancers.
description
1987 nî lūn-bûn
@nan
1987年の論文
@ja
1987年学术文章
@wuu
1987年学术文章
@zh
1987年学术文章
@zh-cn
1987年学术文章
@zh-hans
1987年学术文章
@zh-my
1987年学术文章
@zh-sg
1987年學術文章
@yue
1987年學術文章
@zh-hant
name
Enhanced expression of the c-myc protooncogene in high-grade human prostate cancers.
@en
Enhanced expression of the c-myc protooncogene in high-grade human prostate cancers.
@nl
type
label
Enhanced expression of the c-myc protooncogene in high-grade human prostate cancers.
@en
Enhanced expression of the c-myc protooncogene in high-grade human prostate cancers.
@nl
prefLabel
Enhanced expression of the c-myc protooncogene in high-grade human prostate cancers.
@en
Enhanced expression of the c-myc protooncogene in high-grade human prostate cancers.
@nl
P2093
P2860
P356
P1433
P1476
Enhanced expression of the c-myc protooncogene in high-grade human prostate cancers.
@en
P2093
P2860
P304
P356
10.1002/PROS.2990110405
P577
1987-01-01T00:00:00Z